Anti-HA Antibody Market Share

North American Market

The North America anti-HA antibody market is expected to hold around 36% of the revenue share by the end of 2036. Improvements in technology, like genetic engineering and monoclonal antibody production, have promoted the growth of more powerful and particular anti-HA antibodies which will further be the main reason for the anti-HA antibody market growth of this region. For instance, multiple dozen SARS-CoV-2-distinct mAbs, Tixagevimab + Cilgavimab, Sotrovimab, Regdanvimab, Casirivimab + Imdevimab (Ronapreve), and Bebtelovimab, among others and antiviral medications (Remdesivir, Molnupiravir, and Nirmatrelvir) have been licensed and are accessible in clinical practice in the USA.

European Market Analysis

The Europe region is also predicted to notice an outstanding acceleration in the growth of the anti-HA antibody market in the predicted timeline and the increasing rate of Europeans encountering respiratory disease will wheel the growth of the market. Mortality from respiratory diseases is the third primary reason for death in EU countries, attributing to 8% of all deaths. More than 440,000 people died from respiratory diseases, a growth of 15% over the last year. Most of these fatalities (90%) were among people 65 and over than that years old. The primary reasons for death from respiratory diseases are chronic impeding pulmonary disease, pneumonia, asthma, and influenza.